– EMUNO Therapeutics presents EMT-224, a macrophage-targeting small molecule designed to activate the NLRP3 inflammasome and overcome immune evasion in late-stage colorectal cancer through precision immunotherapy.
– Trince showcases its LumiPore photoporation platform, a high-throughput, non-viral intracellular delivery technology enabling efficient, gentle transfection for drug discovery and cell therapy applications.
– RNhale GmbH introduces ARISE, a project developing RNH003-an inhalable RNA therapeutic for severe asthma—using nano-embedded dry powder technology to address delivery challenges in pulmonary RNA treatments.
– TraffikGene presents a proprietary amphiphilic peptide-based platform for safe, scalable, and targeted nucleic acid delivery, offering a versatile alternative to lipid nanoparticles and viral vectors for RNA therapeutics.
– BiopSense introduces a standardized, automated cartridge-based solution for cell-free DNA extraction from blood, aiming to democratize liquid biopsy diagnostics by improving accessibility, reducing costs, and enabling point-of-care applications in oncology and prenatal testing.
– Alterna Therapeutics, a CRG spin-off, develops splice-switching antisense oligonucleotides (ASOs) to correct disease-associated mRNA splicing alterations, with a pipeline targeting cancers, rare diseases, and undruggable genetic conditions.